Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5-11 Years of Age: A Post Hoc Analysis of a Phase 3 Study (miniSTONE-2).

Jeffery B Baker,Stanley L Block,Steven E Cagas,Laura Burleigh Macutkiewicz, Colleen Collins, Mitra Sadeghi, Sriparna Sarkar,Sarah Williams

The Pediatric infectious disease journal（2023）

引用 0|浏览2

暂无评分

摘要

Safety, efficacy and virological results in children aged 5-11 years were similar to those from the overall study population aged 1-<12 years. Single-dose baloxavir provides an additional treatment option for pediatric patients aged 5-11 years with influenza.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要